ArticleJournal for immunotherapy of cancer2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma.
Howard L Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.